Enoblituzumab, previously known as TJ-271 or MGA271, represents the unique monoclonal targeting CD33, a marker found predominantly on blood populations. The agent works as a dual-action therapy, concurrently connecting https://fayooos085899.blog5.net/93086934/enoblituzumab-a-deep-dive-into-tj-271-and-mga271